Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29840676 | 0.73 | METAP2 (0.49) | NPC1RAB9ACYP19A1 | |
| SCHEMBL2124969 | 0.73 | METAP2 (0.49) | NPC1RAB9ACYP19A1 | |
| SCHEMBL7109285 | 0.72 | — | — | |
| SCHEMBL7453541 | 0.72 | METAP2 (0.32) | — | |
| SCHEMBL4059082 | 0.70 | MDM2 (0.41) | NPC1RAB9ACYP1A2CYP2D6CYP19A1 | |
| SCHEMBL3190484 | 0.70 | MDM2 (0.32) | NPC1RAB9AMDM2 | |
| SCHEMBL8119348 | 0.70 | RAB9A (0.40) | NPC1RAB9A | |
| SCHEMBL16720573 | 0.70 | METAP2 (0.36) | NPC1RAB9ACYP1A2CYP2D6CYP19A1 | |
| SCHEMBL7109711 | 0.70 | BRD4 (0.38) | — | |
| SCHEMBL7447711 | 0.70 | ALDH1A1 (0.38) | CYP2D6CYP19A1CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024039864-A1 | PROTEIN:PROTEIN INTERACTION INHIBITORS | PURDUE RESEARCH FOUNDATION (US) | 2024-02-22 | — | — | WO | disclosed |
| US-20020019534-A1 | Gem substituted hydroxamic acids | PFIZER INC. | 2002-02-14 | — | — | US | disclosed |
| CN-1316995-A | Hydroxy 2-piperidinoate hydroxamic acid derivatives as MMP inhibitors | PFIZER PROD INC (US) | 2001-10-10 | — | — | CN | disclosed |
| EP-1104403-A1 | HYDROXY PIPECOLATE HYDROXAMIC ACID DERIVATIVES AS MMP INHIBITORS | Pfizer Products Inc. (US) | 2001-06-06 | — | — | EP | disclosed |
| WO-2000009485-A1 | HYDROXY PIPECOLATE HYDROXAMIC ACID DERIVATIVES AS MMP INHIBITORS | PFIZER PRODUCTS INC. (US) | 2000-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019534-A1 | Gem substituted hydroxamic acids | MMP14, TOP2A, ADAMTS1 | NPC1 2604/4885RAB9A 1591/4885CYP1A2 1911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.